Back to top

LACOG 0120 – EAP durva lung cancer

  /    /  LACOG 0120 – EAP durva lung cancer

Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil.

Type of Study: Epidemiological

Sponsor / Support: LACOG, GBOT

Primary Objectives: To describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil.

Design: This is a non-interventional/observational cohort study of unresectable stage III NSCLC patients treated with Durvalumab within the EAP in Brazil.

Sample Size: 53 patients

Principal Investigator: Mauro Zukin

Countries LATAM: Brazil Identifier: NCT04948411